Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

Exclusion Criteria

• •Any evidence of clinically active interstitial lung disease (patients with chronic,stable, radiographic changes who are asymptomatic need not be excluded).
• •In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease).
• •Withdrawal, at any time, from the preceding gefitinib study.
• •Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort